----

----

| Delaware                                                       |   | 20-0653570                        |
|----------------------------------------------------------------|--------|-----------------------------------|
| (State or Other Jurisdiction of Incorporation or Organization) |   | (IRS Employer Identification No.) |

| Pharma-Bio Serv Building,#6 Road 696Dorado, Puerto Rico |   | 00646      |
|---------------------------------------------------------|--------|------------|
| (Address Of Principal Executive Offices)                |   | (Zip Code) |

| Large accelerated filer | o | Accelerated filer         | o      |
|-------------------------|---|---------------------------|--------|
| Non-accelerated filer   | o | Smaller reporting company | þ |

----

----

----

| PART III |
|----------|
|     |   |   |   |
| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |   | 4 |
|     |   |   |   |
| ITEM 11. | EXECUTIVE COMPENSATION |   | 7 |
|     |   |   |   |
| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |   | 11 |
|     |   |   |   |
| ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE |   | 13 |
|     |   |   |   |
| ITEM 14. | PRINCIPAL ACCOUNTING FEES AND SERVICES |   | 13 |
|     |   |   |   |
| PART IV  |
|     |   |   |   |
| ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES |   | 14 |

----

| Name                     |   | Age |   | Positions with the Company |   | Director Since |
|--------------------------|--------|-----|--------|----------------------------|--------|----------------|
| Elizabeth Plaza(3)       |   | 51  |   | Chairman of the Board      |   | 2006           |
| Kirk Michel(1),(2)       |   | 59  |   | Director                   |   | 2006           |
| Dov Perlysky(2),(3)      |   | 52  |   | Director                   |   | 2004           |
| Howard Spindel(1)        |   | 69  |   | Director                   |   | 2006           |
| Irving Wiesen(1),(2),(3) |   | 60  |   | Director                   |   | 2006           |

| (1)   | Member of the Audit Committee and Compensation Committee. |
|-----------------|-----------------------------------------------------------|

| (2)   | Member of the Mergers and Acquisition Committee. |
|-----------------|--------------------------------------------------|

| (3)   | Member of the Nominating Committee. |
|-----------------|-------------------------------------|

----

| Name             |   | Age |   | Position                                                                           |   |
|------------------|--------|-----|--------|------------------------------------------------------------------------------------|--------|
| Victor Sanchez   |   | 44  |   | Chief Executive Officer, President and President of European Operations            |
| Pedro J. Lasanta |   | 55  |   | Chief Financial Officer, Vice President - Finance and Administration and Secretary |

----

----

| Name and Principal Position                                                             |   | Fiscal Year |   | Salary |    |   | Bonus  |   |    | OptionAwards ($)(3) |   |   | All OtherCompensation |   |   | Total  |    |
|-----------------------------------------------------------------------------------------|--------|-------------|--------|--------|---------|--------|--------|--------|---------|---------------------|--------|--------|-----------------------|--------|--------|--------|---------|
| Elizabeth Plaza,                                                                        |   | 2014        |   | $      | -       |   |   | $      | -       |                |   | $      | -                     |   |   | $      | 550,754 | (7) |   | $ | 550,754 |   |
| Chairman and Former Principal Executive Officer(1)                                      |   | 2013        |   |   | 105,525 |   |   |   | -       |                |   |   | -                     |   |   |   | 347,067 | (8) |   |   | 452,592 |   |
|                                                                                    |   |        |   |   |    |   |   |   |    |                |   |   |                  |   |   |   |    |   |   |   |   |   |
| Nélida Plaza,                                                                      |   | 2014        |   | $      | 225,600 |   |   | $      | 45,000  | (4)                 |   | $      | 10,879                |   |   | $      | 5,204   | (9) |   | $ | 286,683 |   |
| Former Chief Operating Officer and Secretary(2)                                         |   | 2013        |   |   | 215,023 |   |   |   | 112,500 | (5)            |   |   | 10,879                |   |   |   | 15,612  | (9)  |   |   | 354,014 |   |
|                                                                                    |   |        |   |   |    |   |   |   |    |                |   |   |                  |   |   |   |    |   |   |   |   |   |
| Pedro Lasanta,                                                                          |   | 2014        |   | $      | 158,407 |   |   | $      | -       | (6)                 |   | $      | 10,879                |   |   |   |  - |   |   | $ | 169,286 |   |
| Chief Financial Officer, Vice President –Finance and Administration and Secretary |   | 2013        |   |   | 145,313 |   |   |   | 50,000  | (5)            |   |   | 10,879                |   |   |   | -       |   |   |   | 206,192 |   |

| (1)   | Elizabeth Plaza served as the Principal Executive Officer of the Company from January 1, 2014 to December 31, 2014.  Ms. E. Plaza previously served as the President and Chief Executive Officer of the Company from January 2006 to December 31, 2012. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | Effective November 28, 2014, Nélida Plaza resigned as the Chief Operating Officer and Secretary of the Company.  Ms. N. Plaza previously served as the Acting President and Chief Executive Officer of the Company from January 2013 until December 31, 2013, Vice President of Operations of Pharma-Bio Serv PR, Inc. from January 2004 until December 31, 2013, and the President of Puerto Rico Operations of the Company from December 2009 until December 31, 2013. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)   | Amounts shown do not reflect compensation received by the officers. Instead, the amounts shown are the compensation costs recognized by us in fiscal year 2014 and 2013 for option grants that were made to officers as determined pursuant to FASB ASC Topic 718. The assumptions used to calculate the value of option awards are set forth under Note I – Stock Options and Stock Based Compensation in our audited financial statements for the fiscal year ended October 31, 2014, included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2014. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4)   | Represents bonus for services in fiscal 2014, which were paid in December 2014. |
|-----------------|---------------------------------------------------------------------------------|

| (5)   | Represents bonus for services in fiscal 2013, which were paid in January 2014. |
|-----------------|--------------------------------------------------------------------------------|

| (6)   | The Compensation Committee of the Board of Directors is continuing to evaluate performance for services during the year ended October 31, 2014.  |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

| (7)   | Represents consulting fees and company lease payments for the vehicle under Elizabeth Plaza’s use in the amount of $532,883 and $17,871, respectively.  For additional information regarding these consulting fees, see Employment Agreements – Elizabeth Plaza – Consulting Agreement below. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (8)   | Represents consulting fees and company lease payments for the vehicle under Elizabeth Plaza’s use in the amount of $330,687 and $16,380, respectively.  For additional information regarding these consulting fees, see Employment Agreements – Elizabeth Plaza – Consulting Agreement below. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (9)   | Represents lease payments for the vehicle under the use of Nélida Plaza. |
|-----------------|-------------------------------------------------------------------------------|

----

| Name                    |   | Number of Securities Underlying Unexercised Options Exercisable |   | Number of Securities Underlying Unexercised Options Unexercisable |   | OptionExercisePrice |    | OptionExpirationDate |
|-------------------------|--------|-----------------------------------------------------------------|--------|-------------------------------------------------------------------|--------|---------------------|---------|----------------------|
| Elizabeth Plaza         |   | -                                                               |   | -                                                                 |   | -                   |    | -                    |
| Nélida Plaza(1)(2) |   | 133,400                                                         |   | 66,600                                                            |   | $                   | $0.7200 |                 | Jan. 30, 2017 |
| Pedro Lasanta(1)        |   | 133,400                                                         |   | 66,600                                                            |   | $                   | $0.7200 |                 | Jan. 30, 2017 |

| (1)   | Options to purchase 200,000 shares of common stock were granted on January 30, 2012. These options vest in three annual installments beginning on January 30, 2013. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (1)   | Effective December 15, 2014, the Compensation Committee of the Board of Directors of the Company accelerated the vesting of options to purchase 66,600 shares of common stock of the Company at an exercise price of $0.72 per share previously granted to Nelida Plaza, in connection with her resignation on November 28, 2014. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| Name           |   | Fees Earnedor Paid inCash(1) |   |   | OptionAwards (2)(3) |   |   | Total  |   |
|----------------|--------|------------------------------|--------|--------|---------------------|--------|--------|--------|--------|
| Kirk Michel    |   | $                            | 34,833 |   |                | $      | 9,137  |   |   | $ | 43,970 |   |
| Dov Perlysky   |   | $                            | 34,333 |   |                | $      | 9,137  |   |   | $ | 43,470 |   |
| Howard Spindel |   | $                            | 34,833 |   |                | $      | 9.137  |   |   | $ | 43,970 |   |
| Irving Wiesen  |   | $                            | 34,833 |   |                | $      | 9,137  |   |   | $ | 43,970 |   |

| (1)   | All amounts were earned and paid during fiscal 2014. |
|-----------------|------------------------------------------------------|

| (2)   | Amounts shown do not reflect compensation actually received by the directors. Instead, the amounts shown are the compensation costs recognized by us in fiscal year 2014 for option grants that were made to directors as determined pursuant to FASB ASC Topic 718. The assumptions used to calculate the value of option awards are set forth under Note I – Stock Options and Stock Based Compensation in our audited financial statements for the fiscal year ended October 31, 2014, included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2014. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)   | The options grants have a term of five years from the grant date and an exercise price equal to the fair market value on the date of grant. The options are exercisable as to 50% of the shares six months from the date of grant and as to the remaining 50% 18 months from the date of grant. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Messrs. Perlysky, Spindel, and Wiesen |   | Kirk Michel |   |
|---------------------------------------|--------|-------------|--------|
| Grant Date                            |   | Options     |   |   | Exercise Price |   | Grant Date |   | Options |   |   | Exercise Price |   |
| 1/04/2010                             |   |        | 10,000 |   |   | $ | 0.34 |   | 1/03/2012 |   |   | 10,000 |   |   | $ | 0.70 |   |
| 1/03/2011                             |   |        | 10,000 |   |   | $ | 0.26 |   | 1/02/2013 |   |   | 10,000 |   |   | $ | 0.75 |   |
| 1/03/2012                             |   |        | 10,000 |   |   | $ | 0.70 |   | 1/10/2014 |   |   | 20,000 |   |   | $ | 2.05 |   |
| 1/02/2013                             |   |        | 10,000 |   |   | $ | 0.75 |   |   |   |   |   |   |   |   |   |   |
| 1/10/2014                             |   |        | 20,000 |   |   | $ | 2.05 |   |   |   |   |   |   |   |   |   |   |

| ●   | each director; |
|---------------------|----------------|

| ●   | each officer named in the summary compensation table (“Named Executive Officers”); |
|---------------------|------------------------------------------------------------------------------------------------|

| ●   | each person owning of record or known by us, based on information provided to us by the persons named below, to own beneficially at least 5% of our common stock; and |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ●   | all directors and Named Executive Officers as a group. |
|---------------------|--------------------------------------------------------|

----

| Name                                            |   | Shares ofCommon Stock BeneficiallyOwned atFebruary 23, 2015 |       |   | Percentage |   |
|-------------------------------------------------|--------|-------------------------------------------------------------|------------|--------|------------|--------|
| Directors and Executive Officers                |   |                                                        |       |   |       |   |
| Elizabeth Plaza(1)                              |   |                                                        | 9,169,518  |   |       |   | 39.9 | % |
| Dov Perlysky(2)                                 |   |                                                        | 1,992,326  |   |       |   | 8.6 | % |
| Kirk Michel(3)                                  |   |                                                        | 386,247    |   |       |   | 1.7 | % |
| Howard Spindel(4)                               |   |                                                        | 54,981     |   |       |   | * |   |
| Irving Wiesen(5)                                |   |                                                        | 54,876     |   |       |   | * |   |
| Victor Sanchez(6)                               |   |                                                        | 108,325    |   |       |   | * |   |
| Pedro Lasanta(7)                                |   |                                                        | 222,146    |   |       |   | * |   |
| Nélida Plaza(8)                            |   |                                                        | 87,500     |   |       |   | * |   |
| All Directors and Executive Officers as a group |   |                                                        |       |   |       |   |   |   |
| (seven persons)(9)                              |   |                                                        | 11,988,419 |   |       |   | 51.1 |  % |
| 5% or Greater Stockholders                      |   |                                                        |       |   |       |   |   |   |
| Venturetek, L.P.(10)                            |   |                                                        | 3,132,932  |   |       |   | 13.6 | % |
| Ramon Luis Dominguez Thomas (11)                |   |                                                        | 2,060,060  |   |       |   | 9.0 | % |
| Addison McKinley Levi III (12)                  |   |                                                        | 2,050,059  |   |       |   | 8.9 | % |

| (1)   | Includes 4,099,241 shares owned by Ms. Plaza directly and 5,070,277 shares subject to a voting proxy in favor of Ms. Plaza. In conjunction with certification as a minority controlled business, Ms. Plaza received irrevocable proxies (“Voting Proxies”) to vote an aggregate of 5,070,277 shares of the Company’s common stock from Venturetek LP, Krovim, LLC and LDP Family Partnership. These Voting Proxies are effective until September 26, 2015, unless the business certification expires sooner. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | The shares of common stock beneficially owned by Mr. Perlysky include (i) 14,981 shares directly owned, (ii) 1,164,554 shares of common stock owned by Krovim, LLC, (iii) 772,791 shares owned by LDP Family Partnership and (iv) options issued to Mr. Perlysky to purchase 40,000 shares of common stock, which are vested as of February 23, 2015.  Elizabeth Plaza exercises voting power over the shares owned by Krovim pursuant to a Voting Proxy and Mr. Perlysky as the manager of Nesher, LLC, which is the manager of Krovim, may be deemed to exercise dispositive power over these shares. Mr. Perlysky disclaims beneficial interest in the shares owned by Krovim. Elizabeth Plaza exercises voting power over the shares owned by the LDP Family Partnership pursuant to a Voting Proxy and Mr. Perlysky’s wife, the general partner of LDP Family Partnership, is deemed to exercise dispositive power over these shares. Mr. Perlysky disclaims beneficial ownership in the securities owned by his wife. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)   | The shares of common stock beneficially owned by Mr. Michel consist of (i) 15,541 shares directly owned, (ii) 30,000 shares of common stock issuable upon exercise of options, which are vested as of February 23, 2015, and (iii) 340,706 shares of common stock owned by KEMA Advisors, of which Mr. Michel is managing director. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4)   | The shares of common stock owned by Mr. Spindel represent 14,981 shares owned by his spouse, and 40,000 shares issuable upon exercise of options, which are vested as of February 23, 2015.  Mr. Spindel disclaims beneficial ownership of the shares held by his spouse. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5)   | The shares of common stock owned by Mr. Wiesen, represent 14,876 shares directly owned, and 40,000 shares issuable upon exercise of options, which are vested as of February 23, 2015. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (6)   | The shares of common stock owned by Mr. Sanchez represent 8,325 shares directly owned, and 100,000 shares issuable upon exercise of options, which are vested as of February 23, 2015. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (7)   | The shares of common stock owned by Mr. Lasanta, represent 22,146 shares directly owned, and 200,000 shares issuable upon exercise of options, which are vested as of February 23, 2015. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (8)   | Effective November 28, 2014, Nélida Plaza resigned as Chief Operating Officer and Secretary of the Company.  The number of shares held by Nélida Plaza is based on a Form 4 filed on December 17, 2014. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (9)   | Includes 450,000 shares issuable upon the exercise of options, which are vested as of February 23, 2015. |
|-----------------|----------------------------------------------------------------------------------------------------------|

| (10)   | This information was obtained from Amendment No. 4 to Schedule 13 D/A filed by Venturetek, L.P. ("Venturetek") on September 6, 2011. Does not include 1,565,058 shares underlying warrants, which warrants expired in January 2011, listed in the Schedule 13 D/A filed on January 5, 2011. Mr. David Selengut, the manager of TaurusMax LLC, which is the general partner of Venturetek has sole dispositive power and Elizabeth Plaza has sole voting power over these shares pursuant to a Voting Proxy. The mailing address for Venturetek, L.P. is 150 East 42nd Street, New York, NY 10017. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (11)   | This information was obtained from a Schedule 13D filed by Ramon Luis Dominguez Thomas on March 27, 2014.  The business address for this person is c/o San Juan Holdings, Inc., MCS Plaza, Suite #305, 255 Ponce de Leon Avenue, San Juan, PR, 00917. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (12)   | This information was obtained from a Schedule 13D filed by Addison McKinley Levi III on March 27, 2014.  The business address for this person is c/o San Juan Holdings, Inc., MCS Plaza, Suite #305, 255 Ponce de Leon Avenue, San Juan, PR, 00917. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Plan Category                                      |   | Number of securitiesto be issued uponexercise ofoutstanding options |      |   | Weighted-average exerciseprice per share of outstanding options and warrants |   |   | Number of securitiesremaining available forfuture issuance underequity compensationplans |   |
|---------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------|-----------|--------|----------------------------------------------------------------------------------------------------------------------|--------|--------|-----------------------------------------------------------------------------------------------------------------------------|--------|
| Equity compensation plans approved by security holders: |   |                                                                                                   |      |   |                                                                                                                 |   |   |                                                                                                                        |   |   |   |   |
| 2014 Long-Term Incentive Plan (1)                       |   |                                                                                                   | -         |   |                                                                                                                 | $      | -      |                                                                                                                        |   |   | 2,300,000 |   |
| 2005 Long-Term Incentive Plan (2)                       |   |                                                                                                   | 1,100,000 |   |                                                                                                                 | $      | 0.7985 |                                                                                                                        |   |   | 1,300,000 |   |

| (1)   | The 2014 Long-Term Incentive Plan was approved by stockholders in April 2014. |
|-----------------|-------------------------------------------------------------------------------|

| (2)   | The 2005 Long-Term Incentive Plan was approved by stockholders in April 2006, and amended by stockholder approval in April 2007. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------|

| Description of services: |   | Fiscal 2014 |   |   | Fiscal 2013 |   |
|--------------------------|--------|-------------|--------|--------|-------------|--------|
| Audit                    |   | $           | 49,395 |   |        | $      | 47,600 |   |
| Audit-Related            |   |        | 27,825 |   |        |   | 27,825 |   |
| Tax and other services   |   |        | 22,601 |   |        |   | 19,232 |   |
| Total Fees               |   | $           | 99,821 |   |        | $      | 94,657 |   |

----

| 1.   | All Financial Statements:  Consolidated Financial Statements are included in our Annual Report on Form 10-K filed with the Commission on January 29, 2015 immediately following the signature page of the report. See Index to Consolidated Financial Statements on page F-1 of our Annual Report of Form 10-K filed with the Commission on January 29, 2015. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | Financial Statement Schedules:  None. |
|----------------|-------------------------------------------------|

| 3.   | Exhibits:  The following exhibits are filed herewith or are incorporated by reference to exhibits previously filed with the Commission, as indicated in the description of each. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|           |   |                                                                                                                                                                                                                                                                                                                                               |   | Incorporated By Reference |
|----------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------|
| Exhibit Number |   | Exhibit Description                                                                                                                                                                                                                                                                                                                                |   | Form                      |   | FileNumber |   | Exhibit |   | Filing Date |
| 3.1            |   | Restated Certificate of Incorporation                                                                                                                                                                                                                                                                                                              |   | 8-K                       |   | 000-50956 |   | 99.1 |   | 5/1/2006 |
| 3.1            |   | Certificate of Amendment to the Certificate of Incorporation                                                                                                                                                                                                                                                                                       |   | 8-K                       |   | 000-50956 |   | 3.1 |   | 4/12/13 |
| 3.3            |   | By-laws                                                                                                                                                                                                                                                                                                                                            |   | 10-SB12G                  |   | 000-50956 |   | 3.2 |   | 9/24/2004 |
| 3.4            |   | Amendment No. 1 to the By-laws                                                                                                                                                                                                                                                                                                                     |   | 8-K                       |   | 000-50956 |   | 3.1 |   | 6/6/2008 |
| 3.5            |   | Amendment No. 2 to the By-laws                                                                                                                                                                                                                                                                                                                     |   | 8-K                       |   | 000-50956 |   | 3.2 |   | 4/12/13 |
| 10.1           |   | Consulting Agreement, dated January 7, 2013, by and between Pharma-Bio Serv, Inc. and Elizabeth Plaza.                                                                                                                                                                                                                                        |   | 8-K                       |   | 000-50956 |   | 10.1 |   | 1/11/2013 |
| 10.2           |   | Approval of Compensation Committee, dated July 17, 2013, to increase the hours of service pursuant to the Consulting Agreement between the Company and Elizabeth Plaza (a description of such approval was included in the Company’s Current Report on Form 8-K, filed with the SEC on July 23, 2013, and incorporated herein by reference). |   | 8-K                       |   | 000-50956 |   | - |   | 7/23/13 |
| 10.3           |   | Consulting Agreement, effective January 1, 2014, between Pharma-Bio Serv Inc., Strategic Consultants International, LLC and Elizabeth Plaza.                                                                                                                                                                                                       |   | 8-K                       |   | 000-50956 |   | 10.1 |   | 12/31/13 |
| 10.4           |   | Consulting Agreement, effective January 1, 2015, between Pharma-Bio Serv Inc., Strategic Consultants International, LLC and Elizabeth Plaza.                                                                                                                                                                                                       |   | 8-K                       |   | 000-50956 |   | 10.1 |   | 1/5/2015 |
| 10.5           |   | Employment Agreement, effective January 1, 2015, between Pharma-Bio Serv, Inc. and Victor Sanchez                                                                                                                                                                                                                                             |   | 8-K                       |   | 000-50956 |   | 10.2 |   | 1/5/2015 |
| 10.6           |   | Employment Agreement dated November 5, 2007 between the Pharma-Bio Serv, Inc. and Pedro Lasanta                                                                                                                                                                                                                                          |   | 10-K                      |   | 000-50956 |   | 10.8 |   | 1/29/2009 |
| 10.7           |   | Amendment to Employment Agreement dated December 17, 2008 between the Registrant and Pedro Lasanta                                                                                                                                                                                                                                                 |   | 8-K                       |   | 000-50956 |   | 99.1 |   | 12/23/2008 |
| 10.8           |   | Amendment to Employment Agreement, dated March 11, 2009, by and between the Company and Pedro Lasanta                                                                                                                                                                                                                                              |   | 8-K                       |   | 000-50956 |   | 10.3 |   | 3/17/2009 |
| 10.9           |   | Employment Agreement Amendment, effective as of January 1, 2010, by and between the Company and Pedro Lasanta.                                                                                                                                                                                                                                |   | 8-K                       |   | 000-50956 |   | 10.2 |   | 1/07/2010 |
| 10.10          |   | Employment Agreement Amendment, dated January 31, 2012, by and between the Company and Pedro J. Lasanta                                                                                                                                                                                                                                            |   | 8-K                       |   | 000-50956 |   | 10.1 |   | 2/2/2012 |
| 10.11          |   | Employment Agreement Amendment, dated December 31, 2012, by and between the Company and Pedro J. Lasanta                                                                                                                                                                                                                                           |   | 8-K                       |   | 000-50956 |   | 10.1 |   | 1/7/2013 |
| 10.12          |   | Employment Agreement Amendment between Pharma-Bio Serv, Inc. and Pedro Lasanta, effective January 1, 2014.                                                                                                                                                                                                                                         |   | 8-K                       |   | 000-50956 |   | 10.1 |   | 2/21/2014 |
| 10.13          |   | Employment Agreement, dated as of December 31, 2009, by and between Pharma-Bio Serv PR, Inc. and Nélida Plaza.                                                                                                                                                                                                                           |   | 8-K                       |   | 000-50956 |   | 10.3 |   | 1/07/2010 |
| 10.14          |   | Employment Agreement Amendment, dated January 7, 2013, by and among Pharma-Bio Serv, Inc., Pharma-Bio Serv PR, Inc. and Nélida Plaza                                                                                                                                                                                                          |   | 8-K                       |   | 000-50956 |   | 10.2 |   | 1/11/2013 |
| 10.15          |   | Employment Agreement Amendment, dated January 7, 2013, by and among the Company, Pharma-Bio Serv PR, Inc. and Nelida Plaza                                                                                                                                                                                                                         |   | 8-K                       |   | 000-50956 |   | 10.2 |   | 1/11/13 |
| 10.16          |   | Employment Agreement Amendment among Pharma-Bio Serv, Inc., Pharma-Bio Serv PR, Inc. and Nélida Plaza, effective January 1, 2014.                                                                                                                                                                                                             |   | 8-K                       |   | 000-50956 |   | 10.1 |   | 2/21/2014 |
| 10.17          |   | 2005 Long-term incentive plan, as amended                                                                                                                                                                                                                                                                                                          |   | DEF 14A                   |   | 000-50956 |   | Appendix C |   | 3/26/2007 |
| 10.18          |   | Amendment to 2005 Long-Term Incentive Plan                                                                                                                                                                                                                                                                                                         |   | 10-Q                      |   | 000-50956 |   | 10.4 |   | 3/17/2014 |
| 10.19          |   | Pharma-Bio Serv, Inc. 2014 Long-Term Incentive Plan                                                                                                                                                                                                                                                                                                |   | 8-K                       |   | 000-50956 |   | 10.1 |   | 5/2/2014 |
| 10.20          |   | Lease dated March 16, 2004 between Plaza Professional Center, Inc. and the Registrant                                                                                                                                                                                                                                                         |   | SB-2                      |   | 333-132847 |   | 10.9 |   | 3/30/2006 |
| 10.21          |   | Lease dated November 1, 2004 between Plaza Professional Center, Inc. and the Registrant                                                                                                                                                                                                                                                       |   | SB-2                      |   | 333-132847 |   | 10.10 |   | 3/30/2006 |

----

| 14.1    |   | Code of business conduct and ethics for senior management                                                                            |   | 10-KSB |   | 000-50956 |   | 14.1    |   | 2/2/2007  |
|---------|--------|--------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|-----------|--------|---------|--------|-----------|
| 21.1    |   | List of Subsidiaries                                                                                                            |   | 10-K   |   | 000-50956 |   | 21.1    |   | 1/29/2015 |
| 23.1    |   | Consent of Horwath Vélez & Co, PSC                                                                                          |   | 10-K   |   | 000-50956 |   | 23.1    |   | 1/29/2015 |
| 31.1*   |   | Certification of chief executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                   |   |   |   |      |   |    |   |      |
| 31.2*   |   | Certification of chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                              |   |   |   |      |   |    |   |      |
| 32.1**  |   | Certification of chief executive officer and chief financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  |   |   |   |      |   |    |   |      |
| 101.INS |   | XBRL Instance Document                                                                                                          |   | 10-K   |   | 000-50956 |   | 101.INS |   | 1/29/2015 |
| 101.SCH |   | XBRL Taxonomy Extension Schema                                                                                                  |   | 10-K   |   | 000-50956 |   | 101.SCH |   | 1/29/2015 |
| 101.CAL |   | XBRL Taxonomy Extension Calculation Linkbase                                                                                         |   | 10-K   |   | 000-50956 |   | 101.CAL |   | 1/29/2015 |
| 101.DEF |   | XBRL Taxonomy Extension Definition Linkbase                                                                                     |   | 10-K   |   | 000-50956 |   | 101.DEF |   | 1/29/2015 |
| 101.LAB |   | XBRL Taxonomy Extension Label Linkbase                                                                                          |   | 10-K   |   | 000-50956 |   | 101.LAB |   | 1/29/2015 |
| 101.PRE |   | XBRL Taxonomy Extension Presentation Linkbase                                                                                   |   | 10-K   |   | 000-50956 |   | 101.PRE |   | 1/29/2015 |

----

|                | PHARMA-BIO SERV, INC. |                                                                                     |
|---------------------|-----------------------|------------------------------------------------------------------------------------------|
|                |                  |                                                                                     |   |
| Date: March 2, 2015 | By:                   | /s/ Pedro J. Lasanta                                                                     |   |
|                |                  | Name: Pedro J. Lasanta                                                                   |   |
|                |                  | Title: Chief Financial Officer, Vice President -Finance and Administration and Secretary |   |
|                |                  | (Principal Financial and Accounting Officer)                                             |   |

----

| Exhibit No. |   | Description                                                                                                                                |
|-------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------|
| 31.1        |   | Certification of chief executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                        |
| 31.2        |   | Certification of chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                        |
| 32.1        |   | Certification of chief executive officer required by 18 U.S.C. Section 1350 (as adopted by Section 906 of the Sarbanes-Oxley Act of 2002). |

----